Archives

Loading Events

Major Depressive Disorder In Chronic Kidney Disease

A joint virtual live event for NephU & PsychU members.

In this virtual live event, Alf Carroll, MS, PA-C, and Alyssa Peckham, PharmD, BCPP discuss the high prevalence of major depressive disorder (MDD) among patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD).

Major depressive disorder affects more than 260 million people worldwide.1 The reported prevalence of depression in patients with chronic kidney disease ranges from 20-65%.2 This webinar provides an overview of both MDD and CKD and discusses their overlap of symptomology.

1World Health Organization. Fact Sheet on Depression. (2012) https://www.who.int/health-topics/depression#tab=tab_1
2Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202.

Alf Carroll and Dr Alyssa Peckham are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).

You must be logged in to register for this event. Please Log In or Join Now
Featured Speakers
Alf Carroll

Alf Carroll, MS, PA-C

Nephrology Clinical & Scientific Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Alf Carroll, MS, PA-C is a Clinical & Scientific Liaison at Otsuka Pharmaceutical Development and Commercialization. He earned his Bachelor of Science in Biology and Master of Science in Physician Assistant Studies from Northeastern University in Boston, Massachusetts. He worked clinically as a Physician Assistant in the Emergency Department at Massachusetts General Hospital and South Shore Hospital in the Boston area. Prior to joining Otsuka, Alf held a position at AstraZeneca Pharmaceuticals on their Market Access team focusing on large health systems in New England, covering the cardiovascular, renal, endocrine, and respiratory therapeutic areas.

Alyssa Peckham

Alyssa Peckham, PharmD, BCPP

Medical Science Liaison, Neuroscience
    Otsuka Pharmaceutical Development & Commercialization, Inc.*

Areas of Expertise:

  • Addiction Medicine
  • Mood Disorders
  • Anxiety
  • Schizophrenia
  • Psychopharmacology
  • Public Health
Location

Online